In prion diseases but also in other neurodegenerative diseases,82 therapeutic strategies aimed at lowering/dosing the production of the disease-causing protein are emerging, using chemical compound targeting the unfolded protein response,83 anti-PrP antibodies84,85 or antisense oligonucleotides.86 This evidence concerns the gene PRNP and prion disease.